Why the study?
Echocardiography is the first-line imaging modality for hypertrophic cardiomyopathy, but it often offers limited insights into disease etiology, biological activity, and natural history. Several non-echocardiographic modalities have emerged to address diagnosis and risk stratification beyond the mere detection of left ventricular hypertrophy.
Does integrated multimodality assessment using non-echocardiographic modalities improve disease phenotyping, risk stratification, and clinical management in patients with hypertrophic cardiomyopathy?
Does integrated multimodality assessment using non-echocardiographic modalities improve disease phenotyping, risk stratification, and clinical management in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Integrating non-echocardiographic modalities such as ECG, CMR, and cardiac CT with clinical findings enhances hypertrophic cardiomyopathy phenotyping, differentiates phenocopies, and refines risk stratification for sudden cardiac death to guide personalized care and ICD placement.
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic and phenotypic myocardial disease where diagnosis and risk stratification extend beyond the mere detection of left ventricular hypertrophy. While echocardiography is the first-line imaging modality, this approach often offers limited insights into disease etiology, biological activity, and natural history. Thus, several non-echocardiographic modalities have emerged as prominent components of contemporary HCM investigations. Electrocardiography (ECG) provides early, readily accessible insights into myocardial remodeling and arrhythmic risk. Cardiac magnetic resonance (CMR) imaging enhances phenotyping through detailed tissue characterization and fibrosis assessment, while nuclear imaging uniquely evaluates myocardial perfusion and microvascular injury. Plasma biomarkers and genetic testing offer valuable insights into disease activity and risk stratification for affected individuals and at-risk relatives, especially when combined with imaging findings. Therefore, this review summarizes current knowledge on non-echocardiographic approaches to HCM, highlighting the associated complementary strengths and the value of integrated multimodality assessment in improving disease phenotyping, prognostication, and management. Importantly, integrating these modalities improves risk stratification for sudden cardiac death, heart failure progression, and arrhythmias, guiding decisions on implantable cardioverter-defibrillator (ICD) placement and medical management. This approach supports more personalized, mechanism-based care in HCM.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Non-echocardiographic diagnostic modalities (ECG, cardiac CT, CMR, nuclear imaging, biomarkers, and genetic testing) vs. Echocardiography was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: